Amgen (AMGN) reports Q3: everything you need to know ahead of earnings

What happened

Amgen is scheduled to report its third-quarter results Tuesday after market hours. The article says it beat analysts’ revenue expectations last quarter, with revenue of $10.05 billion, up 9.5% year on year, and that this quarter analysts expect revenue growth of 5.2%.

Confirmed

Global impact / market context

The reported slowdown in expected revenue growth matters because sales growth helps show whether demand is expanding. If Amgen reports above or below the 5.2% expectation, investors may reassess future revenue expectations and the value they place on its shares; the article gives no earnings result yet.

Analyst inference

Analysts generally reconfirmed their estimates in the 30 days before the report, while the article says Biogen and Gilead exceeded revenue expectations. Their differing share-price moves after results—down 1.2% for Biogen and up 4.1% for Gilead—show that strong sales alone did not dictate the immediate response.

Confirmed

What to watch

1. Amgen’s reported third-quarter revenue versus the 5.2% year-on-year growth analysts expect; a larger or smaller result could shift expectations for future sales. Analyst inference
2. Any updated full-year revenue guidance, meaning management’s forecast for the year, since last quarter Amgen’s guidance exceeded analysts’ expectations. Analyst inference
3. Whether Amgen’s share-price response resembles Biogen’s 1.2% decline or Gilead’s 4.1% rise after their results; the article reports these moves but gives no cause. Analyst inference

Evidence

• stockstory.org